About the Company
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
111
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EVLO News
Evelo Biosciences Inc EVLO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines ...
Why Root Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Evelo Biosciences, Inc. (NASDAQ: EVLO) fell 8.4% to $0.1465 in pre-market trading after dropping 9% on Wednesday. Catalyst Biosciences, Inc. (NASDAQ: CBIO) shares dropped 8.3% to $0.32 in pre ...
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
SPRB Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont ...
Evelo Biosciences, Inc. (EVLO)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Evelo Biosciences, Inc. (EVLO)
Horizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Greetings, and welcome to Horizon Technology Finance Corporation Third Quarter 2023 ...
Loading the latest forecasts...